Search results
Results from the WOW.Com Content Network
Aripiprazole, sold under the brand names Abilify and Aristada, among others, is an atypical antipsychotic. [8] It is primarily used in the treatment of schizophrenia and bipolar disorder ; [ 8 ] other uses include as an add-on treatment in major depressive disorder , tic disorders . [ 8 ]
Dizziness; Dyspepsia — indigestion; Somnolence — which is usually mild and transient and less severe than that seen with most antipsychotics. [6]Fatigue; Restlessness; Dry mouth
Venlafaxine has also been implicated to create withdrawal symptoms regardless of dosage. [15] Venlafaxine has been implicated in causing the most severe withdrawal symptoms after cessation of use, possibly due to its short half-life. [16] To simplify identifying the principal signs and symptoms, the mnemonic FINISH may be used: Flu-like ...
The approval of aripiprazole lauroxil from the Food and Drug Administration in 2015 was solely for the treatment of schizophrenia in adults. The ability to supplement aripiprazole lauroxil with oral supplements of aripiprazole allows for dosing flexibility, which is important for the treatment of schizophrenia, as symptoms and intensity of the disease vary greatly from patient to patient.
Research shows men are more likely than women to avoid—or delay—necessary medical care, even when their symptoms disrupt their lives or become chronic. An online survey conducted by the ...
Therefore, men are more likely to develop severe symptoms of anxiety and possibly develop an additional depressive disorder due to the lack of treatment intervention.”
The first symptoms of neuroleptic malignant syndrome are usually muscle cramps and tremors, fever, symptoms of autonomic nervous system instability such as unstable blood pressure, and sudden changes in mental status (agitation, delirium, or coma). Other possible symptoms include sweating, trouble swallowing, tremors, incontinence, and mutism.
The magnitude of the connection between cannabis and schizophrenia for young men surprised study author Volkow, who was expecting the number to be closer to 10%. “This is worrisome,” she said.